Basel pharmaceutical wins start-up competition

Yvonne von Hunnius, BaselArea/ Café Europe
The start-up developed a proprietary protein technology based on live bacteria. (Generic Image)
The start-up developed a proprietary protein technology based on live bacteria. (Generic Image)

The start-up company T3 Pharmaceuticals won the "venture" start-up competition in the Business Plan category.

The start-up develops innovative therapies to treat cancer patients and developed a proprietary protein technology based on live bacteria. T3 Pharmaceuticals was founded as a spin-off of the University of Basel in 2015. Co-founders Simon Ittig and Christoph Kasper manage the company today as CEO and Chief Scientific Officer. Numerous foundations and academic institutions are among the T3’s supporters.

The venture start-up competition was launched by the Federal Institute of Technology (ETH) in Zurich and companies to help unlock the innovation potential of start-ups. venture is supported by a number of renowned companies and describes itself as the leading start-up competition in Switzerland.

The winners were honoured on Thursday in two categories: Business Idea and Business Plan. The winners were selected from five finalists in each category. All ten finalists will split a total of CHF 150,000 in prize money.

Public Pictures